<DOC>
	<DOCNO>NCT01559142</DOCNO>
	<brief_summary>The aim study confirmation efficacy induction therapy three dos infliximab In patient Crohn disease age 7-17 year , comparison efficacy safety two regiment maintenance therapy : 1 . Infliximab immunomodulation 2 . Infliximab alone</brief_summary>
	<brief_title>Efficacy Safety Two Regimens Maintenance Therapy Children With Crohn Disease</brief_title>
	<detailed_description>Study project Screening ( Days -14 0 ) : Laboratory endoscopic ( three month Day 0 ) result obtain check inclusion/exclusion criterion . Part A ( Days 1 71 ) : Induction therapy 3 dos infliximab 5 mg/kg apply day 1 - 15 - 43 . Simultaneously patient receive steroid , steroid tapering perform 71 Day . At Day 71 clinical ( PCDAI ) endoscopic assessment do . Patients clinical response qualify Follow-up surveillance group . Patients clinical response present randomize two group maintenance therapy : 1 . Infliximab immunomodulation 2 . Infliximab alone Part B ( Weeks 10 - 54 ) : Patient group schedule visit Weeks 14 , 22 , 30 , 38 , 46 . Infliximab infusion laboratory test perform visit . At Week 54 clinical ( PCDAI ) endoscopic assessment do . Follow Up : 4 week last visit - SAE monitoring Aim study The aim study confirmation efficacy induction therapy three dos infliximab In patient Crohn disease age 7-17 year , comparison efficacy safety two regiment maintenance therapy : 1 . Infliximab immunomodulation 2 . Infliximab alone Drug dose therapy regimen . Infliximab : 5 mg/kg mc In intravenous infusion last 2 hr . Azathioprine : 1,5 - 3 mg/kg/24h Methotrexate : 10 - 25 mg/week Safety assessment AE SAE monitoring conduct whole period study Efficacy assessment Primary endpoint Part A : • Clinical response define : Decrease PCDAI ≥ 15 point AND PCDAI less 30 point • Remission define : PCDAI ≤ 10 point Part B : - Loss clinical response define : Increase PCDAI 15 point OR PCDAI &gt; 30 point Secondary endpoint Part A : • Time steroid cessation Part B : • Necessity increase/change maintenance therapy Surgery Increase infliximab dose - Increase immunomodulator dose - Steroids induction Statistical method - ITT analysis - Primary endpoint : chi2 test , Kaplan-Meier analysis - Secondary endpoint : chi2 test , Kaplan-Meier analysis , U Mann-Whitney analysis</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . Patients severe Crohn disease ( PCDAI anamnesis 51 point ) , PCDAI currently 30 point , loss response previous therapy ( except biological agent ) . Patients may active fistula . 2 . Efficient method contraception patient childbearing potential study period six month . 3 . Patients enrol Part B study whether finish Part A clinical remission clinical response . 1 . Hypersensitivity infliximab 2 . Pregnancy breastfeed 3 . Active tuberculosis severe infection : sepsis , opportunistic infection , active CMV , yersinia pseudotuberculosis , pneumocystis carini , atypical mycobacteriosis 4 . VZV infection , hepatitis , pneumonia 3 month Day 0 study 5. pancytopaenia aplastic anemia 6. moderate severe heart insufficiency ( NYHA class III/IV ) , unstable coronary heart disease 7. chronic pulmonary insufficiency , chronic renal insufficiency , chronic liver insufficiency 8 . HIV infection 9 . Presence severe diseases nervous system severe endocrinological , hematological , psychiatric disease . 10 . Demyelinisation syndrome symptom resemble Demyelinisation syndrome 11 . Malignancy premalignant condition 5 year Day 0 study . 12 . Severe infection currently present 13 . Malignancy currently present</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Crohn Disease</keyword>
	<keyword>infliximab</keyword>
	<keyword>azathioprine</keyword>
</DOC>